Monograph
C03AB01 - Bendroflumethiazide and Potassium |
Propably not porphyrinogenic |
PNP |
Rationale
Sulfonamide type of drug. Clinical experience points to non-porphyrinogenicity. There are references that warn against the drug. Combined with potassium chloride.
Therapeutic characteristics
Thiazide diuretic and antihypertensive.
Metabolism and pharmacokinetics
The major part of the drug is eliminated via non-renal mechanisms, only 30 % excreted in unchanged form in urine. More specific data on metabolism are lacking. No observations of CYP interaction. Bendroflumethiazide is a sulfonamide type drug, a drug group often incriminated in acute porphyric attacks. Combined with potassium chloride.
Personal communication
Thunell, patient report (n=1): tolerated. Andersson, patient report (n=11): tolerated.
Published experience
None.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Pharmacokinetics of bendroflumethiazide.
Beermann B, Groschinsky-Grind M, Lindstrom B. Clin Pharmacol Ther. 1977 Oct;22(4):385-8. PMID: 902450 |
902450 |
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Denmark
Norway
Iceland© NAPOS 2024